BioTime Completes Merger of XenneX, Inc. into LifeMap Sciences, Inc. ALAMEDA, Calif.--(BUSINESS WIRE)

Completes Merger of XenneX, Inc. into LifeMap Sciences, Inc.

ALAMEDA, Calif.--(BUSINESS WIRE)--May 21, 2012--BioTime, Inc. (NYSE MKT:

BTX) and its subsidiary LifeMap Sciences, Inc. today announced that they

have completed the acquisition of XenneX, Inc. through a merger of

XenneX into LifeMap Sciences. The definitive merger agreement was

previously announced on April 20, 2012.

LifeMap Sciences now holds the exclusive, worldwide licenses to market GeneCards

and PanDaTox from Yeda Research and Development Company Ltd, the

technology transfer arm of the Weizmann Institute of Science in Israel.

Developed by a leading bioinformatics team at the Weizmann Institute of

Science, GeneCards is an online database that

provides concise genomic, transcriptomic, genetic, proteomic, functional

and disease-related information on all known and predicted human genes.

With over 12 million page visits per year from hundreds of thousands of

unique users worldwide, GeneCards is used by

academia, research hospitals, patent offices, and leading biotech and

pharma companies. PanDaTox is a recently developed, searchable

database that can aid in the discovery of new antibiotics and

biotechnologically beneficial products.

LifeMap Sciences' goal is to be the leading resource for the emerging

field of regenerative medicine, by providing access to GeneCards ,

and its LifeMap database of embryonic development and stem

cells, and by also marketing research products manufactured by BioTime,

including ACTCellerateTM cell lines, HyStem

hydrogels, and cell culture media.

LifeMap scientists will also utilize its databases to aid in the

development of BioTime's proprietary ACTCellerate human

progenitor cell lines into products for the treatment of human diseases,

especially degenerative diseases that might be treatable by cell

replacement therapies.

Since 2003, XenneX has been commercializing GeneCards worldwide.

Its customers include biotechnology, pharmaceutical and other life

sciences companies, as well as organizations dealing with biotechnology

intellectual property.

Through the merger, XenneX stockholders received 1,362,589 shares of

LifeMap Sciences common stock, which represents approximately 13% of the

LifeMap Sciences common stock now outstanding. XenneX shareholders also

received 448,431 BioTime common shares as part of the transaction.

"The need for the LifeMap database is a reflection of the growth of the

field of regenerative medicine," said Michael D. West, Ph.D., BioTime's

Chief Executive Officer. "And the pace of this research is currently

exponential, not linear. As a result, the scientific community today is

very dependent on such relational databases. The LifeMap team is

dedicated to building a quality resource in order to speed stem

cell-based therapies to the clinic."

David Warshawsky, Ph.D., LifeMap Sciences Chief Executive Officer, who

also founded XenneX, Inc. in 2003, stated "By marketing GeneCards

and PanDaTox, and the newly licensed MalaCards

human disease database, alongside its LifeMap stem cell database

and discovery platform, LifeMap Sciences will be the leading source of

online database research tools for genetic, biological, and stem cell

research and development. We are confident that our products will

enhance research and provide life-saving cures in the future."

About LifeMap Sciences, Inc.

LifeMap Sciences' (www.lifemapsc.com) core technology and

business is based on its integrated database suite, The go-to

discovery and marketing platform for biomedical and stem-cell research.

This platform will include GeneCards : the

leading human gene database; the LifeMap database of

embryonic development, stem cell research and regenerative medicine; and MalaCards,

the human disease database. LifeMap Sciences also markets PanDaTox,

a recently developed, searchable database that can aid in the discovery

of new antibiotics and biotechnologically beneficial products.

In addition to database offerings, BioTime plans to make LifeMap

Sciences BioTime's principal marketing subsidiary for research products,

including ACTCellerate human progenitor cell lines, GMP human

embryonic stem (hES) cell lines, hES cell lines carrying inherited

genetic diseases, and ESpan growth media for progenitor cell lines for

non-therapeutic uses. LifeMap Sciences will utilize its databases as

part of its online marketing strategy to reach life sciences researchers

at biotech and pharmaceutical companies and at academic institutions and

research hospitals worldwide.

In a therapeutic discovery collaboration with BioTime, LifeMap's

scientists will utilize LifeMap's proprietary discovery platform and

stem cell database along with the GeneCards and

MalaCards integrated database suite, to aid in the development of

BioTime's proprietary ACTCellerate human progenitor

cell lines into products for the treatment of human diseases, especially

degenerative diseases that might be treatable with cell replacement

therapies. The LifeMap discovery platform will be used to

select the progenitor cell lines that are most likely to be useful in

developing cell-based regenerative medicine therapies for a wide range

BioTime, headquartered in Alameda, California, is a biotechnology

company focused on regenerative medicine and blood plasma volume

expanders. Its broad platform of stem cell technologies is developed

through subsidiaries focused on specific fields of applications. BioTime

develops and markets research products in the field of stem cells and

regenerative medicine, including a wide array of proprietary ACTCellerate

cell lines, HyStem hydrogels, culture media, and

differentiation kits. BioTime is developing Renevia (formerly

known as HyStem -Rx), a

biocompatible, implantable hyaluronan and collagen-based matrix for cell

delivery in human clinical applications. As an injectable product, Renevia

may address an immediate need in cosmetic and reconstructive surgeries

and other procedures by improving the process of transplanting adipose

derived cells, mesenchymal stem cells, or other adult stem cells.

BioTime's wholly owned subsidiary ES Cell International Pte. Ltd. has

produced clinical-grade human embryonic stem cell lines that were

derived following principles of Good Manufacturing Practice and

currently offers them for use in research. BioTime's therapeutic product